ACIU
ACIU
NASDAQ · Biotechnology

Ac Immune Sa

$2.19
+0.08 (+3.79%)
As of Nov 7, 2:14 AM ET ·
Financial Highlights (FY 2026)
Revenue
3.63M
Net Income
-71,485,007
Gross Margin
—
Profit Margin
-1,971.7%
Rev Growth
-2.9%
D/E Ratio
0.10
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 67.7% 67.7%
Operating Margin -1,940.0% -1,746.0% 0.2% 0.2%
Profit Margin -1,971.7% -1,873.1% 0.2% 0.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 3.63M 3.74M 119.79M 119.57M
Gross Profit — — 81.15M 81.00M
Operating Income -70,413,319 -65,251,222 217.2K 194.6K
Net Income -71,485,007 -66,244,343 199.8K 200.3K
Gross Margin — — 67.7% 67.7%
Operating Margin -1,940.0% -1,746.0% 0.2% 0.2%
Profit Margin -1,971.7% -1,873.1% 0.2% 0.2%
Rev Growth -2.9% -2.9% -0.9% +8.9%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 10.29M 10.29M 114.17M 132.63M
Total Equity 101.66M 101.66M 166.00M 182.25M
D/E Ratio 0.10 0.10 0.69 0.73
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -67,804,429 -66,324,348 316.5K 305.4K
Free Cash Flow — — 248.3K 178.6K